39 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
23 May 24
Regulation FD Disclosure
5:05pm
conducted under a Special Protocol Assessment with the FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
About
8-K
EX-99.1
CADL
Candel Therapeutics Inc
25 Apr 24
Candel Therapeutics Announces Upcoming Presentations
8:30am
phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA. The FDA has also granted Orphan Drug Designation
8-K
EX-99.1
ploznk7 7kv5
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
8-K
EX-99.1
8br1g3 nf
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
8-K
EX-99.1
poh5697 ohfh4n
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
8-K
EX-99.1
2cv9cqcvigut
19 May 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
tj373biskue2r39zb
6 Dec 22
Regulation FD Disclosure
8:01am
DEF 14A
mj7 m16ki
2 Sep 22
Definitive proxy
8:30am